Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors

Overview of attention for article published in Frontiers in Bioengineering and Biotechnology, February 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 63 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,508 followers.

Publication in Frontiers in Bioengineering and BioTechnology (Mar 2020): Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors: https

02 Apr 2020

Reply Repost Favourite

New article: Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. https://t.co/FKg4IHYWyI #pancreaticcancer #oncology

12 Mar 2020

Reply Repost Favourite

New Research: Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors: The survival rate of patients with… https://t.co/aZDjFudigb #bio

25 Feb 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.